As we are fast approaching 2024 GOLD have released a revised report with several changes and new additions, with 148 new references being added.
The key changes;
Information about PRISm has been expanded, a new section on hyperinflation, and clarification about pre-bronchodilator spirometry.
– The section on smoking cessation has been revised, and a new section on pharmacotherapies for smoking cessation has been added including NRT, vaping/e-cigarettes and pharmacological products.
– Screening for COPD in targeted populations with information on leveraging lung cancer imaging for COPD screening , including spirometry screening in targeted populations, and leveraging Incidental lung imaging abnormalities for COPD screening.
– In the initial assessment section, the paragraphs on blood eosinophil count have been updated.
– Interstitial lung abnormalities are now included, given the clinical relevance, many studies support clinical evaluation, risk stratification and follow up of individuals with findings of interstitial lung abnormalities.
– Vaccination recommendations for people with COPD have been updated in line with current guidance from the US Centers for Disease Control (CDC); influenza, COVID-19, pneumococcal, respiratory syncytial virus, Tdap and zoster vaccinations.
– Managing Inhaled Therapy has been expanded including information on a patient’s ability to use the delivery system correctly and choice of inhaler device.
Joanne Thompson, COPD Lead, ARNS Respiratory Disease Sub CommitteeÂ